Multicellular organisms require strict growth control mechanisms to ensure that an organ reaches, but does not grossly exceed, its appropriate size and shape. In an unbiased mosaic screen for genes involved in growth regulation, we identified a loss-of-function allele of the gene CtBP that conferred a growth advantage to homozygous mutant tissue. CtBP encodes a transcriptional co-repressor found in diverse organisms, yet its role in regulating tissue growth is not known. We found that CtBP functions as a negative regulator of growth by restricting the expression of the growth-promoting microRNA bantam (ban). ban is a known target of the Hippo pathway effector Yorkie (Yki). We show that loss of CtBP function leads to the activation of a minimal enhancer of ban via both Yki-dependent and AP-1 transcription factor-dependent mechanisms. AP-1 is downstream of the Jun N-terminal Kinase (JNK) pathway and thus JNK could regulate growth during development via ban. Furthermore, we show that distinct isoforms of the AP-1 component Fos differ in their ability to activate this enhancer. Since the orthologous pathways in mammalian cells (YAP/TEAD and AP-1) converge on enhancers implicated in tumor progression, a role for mammalian CtBP proteins at those enhancers merits attention.
Introduction
Tissue growth is a fundamental aspect of animal development. Strict control mechanisms are needed to ensure that an organ does not exceed its correct size at the end of development, and to allow for regenerative growth upon tissue damage. Although individual cells are the generators of biomass, organs composed of thousands of cells are able to stop growing when they reach a predictable size and shape. The mechanisms that link the size and shape of the organ to the proliferation of thousands of individual cells are still poorly understood.
The Hippo pathway, initially discovered in Drosophila, is essential for normal development and plays a key role in growth control, through the coordinated regulation of cell proliferation and apoptosis (recently reviewed by (Misra and Irvine, 2018; Zheng and Pan, 2019) ). Many of the pathway components found in Drosophila are shared among diverse metazoans (Sebe-Pedros et al., 2012) , with great functional conservation in mammals; (Zhao et al., 2011) . The Drosophila Hippo pathway restricts tissue growth by inhibiting the nuclear localization of the transcriptional coactivator Yorkie (Yki) (Huang et al., 2005) Yki does not bind DNA itself, but is targeted to specific loci in the genome via its association with sequence-specific DNA binding proteins, most notably Scalloped (Sd) (Wu et al., 2008; Zhang et al., 2008) . Yki has also been proposed to function in complex with other DNA binding proteins as well including Teashirt and Homothorax in the eye disc (Peng et al., 2009) and Mad (Oh and Irvine, 2011) although these claims have been contested (Yu and Pan, 2018) . Under pro-growth conditions, Yki can accumulate in the nucleus, where it activates numerous target genes. Among Yki targets is the microRNA bantam (ban), which is capable of both promoting growth and inhibiting cell death (Nolo et al., 2006; Thompson and Cohen, 2006) .
While we are far from a complete understanding of the transcriptional program downstream of Yki that defines its role in developmental growth, mounting evidence suggests that the components of this program are likely subject to multiple regulatory inputs. Indeed, several studies have demonstrated that Yki-dependent regulatory enhancers often contain consensus binding sites for the transcriptional effectors of other conserved signaling pathways (Oh et al., 2013; Pascual et al., 2017) . A transcription factor that has been shown to have binding sites in the genetic loci for many Yki targets is AP-1 (Pascual et al., 2017) , the downstream transcriptional effector of the c-Jun amino-terminal kinase (JNK) pathway (Eferl and Wagner, 2003) . The JNK pathway is a kinase cascade involved in several morphogenetic processes during development and is activated in response to various stress stimuli. JNK signaling has been shown to trigger apoptosis or tumorigenesis, depending on the genetic context, via activation of AP-1. AP-1 are homodimeric and heterodimeric protein complexes consisting of the bZIP-domain containing proteins Fos and Jun. As in Drosophila, studies using human cancer cell lines have shown that the human orthologs of Yki, YAP and TAZ, localize to enhancers in complex with the Sd ortholog TEAD4 in proximity to AP-1 binding sites and that TEAD/YAP and AP-1 synergistically regulate the expression of genes that promote cancer progression (Verfaillie et al., 2015; Zanconato et al., 2015; Liu et al., 2016) . The mechanisms that regulate synergy between these two pathways are still not well characterized.
We had previously identified CtBP, which encodes a transcriptional corepressor, in a screen for genes that regulate regenerative plasticity (Worley et al., 2018) . In a separate screen, we identified an allele of CtBP as a mutation that enables mutant cells to outgrow their wild-type neighbors. Here we characterize the role of CtBP as a negative regulator of growth and show that this is due, in significant part, to its effect on reducing expression of the growth effector ban. We show that CtBP regulates a minimal ban enhancer via both yki-dependent and ykiindependent mechanisms. In addition to yki, we show that the JNK/AP-1 pathway can activate this enhancer and that CtBP appears capable of antagonizing both of these pathways. Thus, CtBP maintains the appropriate level of growth during development by modulating the activity of both the Yki and JNK/AP-1 pathways.
Materials and Methods

Drosophila stocks and husbandry
Crosses were maintained on standard fly food at 25°C unless otherwise noted. For experiments sensitive to the effects of developmental staging and vial density, egg deposition was limited to a 4 h window.
The CtBP A147T allele is an EMS mutation induced on an FRT82B chromosome. The CtBP Q229* allele (BDSC 1663) has been described as a null allele and was recombined onto the parental FRT82B chromosome for use in this study. The CtBP N148fs mutation was generated on the FRT82B chromosome using CRISPR/Cas9 and a guide RNA targeting codon 148.
Additional stocks used were: FRT82B (Xu and Rubin, 1993) , GFP-ban (bantam sensor, (Brennecke et al., 2003) ); ban3-GFP (Matakatsu and Blair, 2012) ; ex 697 (Boedigheimer and Laughon, 1993) ; Diap1 3.5-GFP (Zhang et al., 2008) ; FRT42D yki B5 (Huang et al., 2005) ; FRT42D MARCM ; UAS-ban-sponge (Becam et al., 2011) ; UAS-Fos.D (Ling et al., 2012) .
Remaining stocks used in this study were from, or derived from, the Bloomington Stock Center (Bloomington, IN): FRT82B ubi-RFPnls (BDSC 30555); FRT82B MARCM (BDSC 30036); UbxFlp; FRT42D GFP; FRT82B RFP (BDSC 43340); FRT82B kay ED6315 (BDSC 41772); brC12-lacZ (BDSC 44256); puc A251.1F3 (BDSC 11173); nub-Gal4 (BDSC 25754); ptc-Gal4 (BDSC 2017); UAS-GFP (BDSC 6874); UAS-yellow-shRNA (BDSC 64527); UAS-CtBP-shRNA (BDSC 32889); UAS-puc-shRNA (BDSC 53019); UAS-Hep-WT (BDSC 9308); UAS-Bsk-DN (BDSC 9311); UAS-bsk-shRNA (BDSC 57035); UAS-Fos (BDSC 7213); UAS-fos-shRNA (BDSC 33379); UAS-Jun (BDSC 7216).
Cloning and molecular biology
Transgenic UAS-CtBP-HA stocks for overexpression of each unique CtBP protein isoform were generated for this study and integrated at the attP40 landing site. We generated a stable transgenic with a CRISPR guide RNA targeting a conserved region in the CtBP gene, following the method described in the FlyCas9 system (Kondo and Ueda, 2013) .
Clonal Analysis
For the clone and twin-spot quantification experiments shown in Figure 1 , clones were induced 48 h after egg deposition with a 45±15 min heat-shock at 37°C and wing imaginal discs were dissected 72 h later. For an individual mosaic disc, the total clone area was determined by tracing all the RFP-negative clones and adding up their areas, and the total twin-spot area was determined by tracing all the 2 RFP-positive clones and adding up their areas.
For the MARCM experiments shown in Figures 2 and 3, clones were induced 48 h after egg deposition with an hour-long 37°C heat-shock, and wing imaginal discs were dissected 72 h later. Individual clones were traced using the Polygon tool and measured in ImageJ.
Immunostaining and Antibodies
Imaginal discs were dissected from wandering third instar larvae were fixed in PBS + 4% paraformaldehyde for 20 minutes at room temperature, washed and permeabilized in PBS + 0.1% Triton-X, and blocked in PBS + 0.1% Triton-X + 5% goat serum (G9023, Sigma) or donkey serum (D9663, Sigma). Primary antibody stains were performed overnight at 4°C, while secondary antibody stains were performed for 2-4 hours at room temperature.
Primary antibodies were diluted in the same solution used for the blocking step and used at the following concentrations: 1:50 goat anti-dCtBP (dN-20, Santa Cruz Biotechnology); 1:500 rabbit anti-cleaved DCP-1 (9578S, Cell Signaling Technology); 1:500 rabbit anti-β-Galactosidase (559762, MP Biomedicals); 1:500 mouse anti-β-Galactosidase (Sigma); 1:500 mouse anti-GFP; 1:500 rabbit anti-HA (C29F4, Cell Signaling Technology); 1:400 guinea pig anti-Yki; 1:1000 rabbit anti-dFos (a gift from D. Bohmann). Alexa Fluor-conjugated secondary antibodies were from Thermo Fisher Scientific and diluted 1:500 in the appropriate blocking solution. Nuclei were visualized with DAPI (1:1000). Tissues were mounted in SlowFade Diamond Antifade Mountant (Thermo Fisher Scientific). Confocal images were obtained on a Zeiss LSM 700 and processed using ImageJ.
Imaging and processing of adult structures
Adult structures were imaged using a Leica transmitted light microscope (TL RCI, Germany).
For adult wing experiments, wings were removed from adult females and mounted onto slides using Gary's Magic Mounting Medium. The outline of each wing was traced using the Polygon tool beginning at the alar-costal break, and the bound area was quantified in ImageJ.
Results
CtBP is a negative regulator of tissue growth
In an unbiased mosaic screen for genes involved in growth regulation (described in (Tapon et al., 2001) ), we identified an allele of the gene CtBP that conferred a growth advantage to homozygous-mutant tissue. Homozygous mutant clones of this allele, CtBP A147T , generated by eyFlp/FRT-mediated mitotic recombination, were overrepresented in the adult eye when compared to clones of the parental FRT82B chromosome (Figure 1A-B ). Conserved orthologs of CtBP are found in diverse taxa. It encodes a transcriptional co-repressor and was originally identified for its ability to bind the C-terminus of the adenovirus E1A oncoprotein in mammalian cells (Boyd et al., 1993) . Subsequent work has shown that, in both vertebrates, which have two CtBP genes, and invertebrates, which have just one, the CtBP proteins can form interactions with a large number of DNA-binding transcriptional repressors to regulate gene expression (reviewed in (Turner and Crossley, 2001; Chinnadurai, 2007) ). Many of these repressors possess a PxDLS motif that is important for CtBP-binding. In Drosophila, the CtBP gene is predicted to produce multiple short (379-386 a.a.) and long (473-481 a.a.) protein isoforms via alternative splicing (Figure 1E and Supplementary figure S1 ).
The CtBP A147T allele failed to complement the lethality of a previously described null allele of CtBP (CtBP 87De-10 , which we will refer to henceforth by its nonsense mutation CtBP Q229* ). This null allele causes embryonic lethality in homozygous animals, while animals homozygous for the CtBP A147T allele survive to the late pupal stage, suggesting that the CtBP A147T allele recovered in our screen is a hypomorph. It has been reported previously that CtBP Q229* clones are larger than wild-type clones in mosaic eye imaginal discs (Hoang et al., 2010) . We observe this result as well ( Figure 1C) , with adult eyes consequently exhibiting large mutant clones. In addition to this published null allele (Poortinga et al., 1998) , we used CRISPR/Cas9-directed mutagenesis to generate an allele of CtBP with a 13-bp deletion at amino acid position 148 on the FRT82B chromosome. The deletion causes a frameshift mutation, CtBP N148fs , and consequent premature stop codon. Mutant clones of this likely null allele also display a growth advantage in mosaic eyes ( Figure 1D ).
Owing to its pleiotropic effects on gene expression, Drosophila CtBP has been implicated in a number of developmental processes, including embryonic segmentation (Nibu et al., 1998; Poortinga et al., 1998) and appendage patterning (Biryukova and Heitzler, 2008; Hoang et al., 2010 ), yet less is known about its specific function in tissue growth control. While our results are consistent with a previous report's findings that CtBP regulates tissue growth within the developing eye (Hoang et al., 2010) , its mechanistic basis is not known. To first determine whether CtBP also had similar functions in other imaginal discs, we generated CtBP mutant clones throughout the imaginal discs using hsFlp/FRT-mediated mitotic recombination.
Because the CtBP mutation is flipped over an FRT chromosome bearing a fluorescent marker, we could directly compare the area of CtBP mutant tissue, marked by the absence of the fluorescent marker, to that of the wild-type twin-spot tissue. We found that for all three CtBP alleles, homozygous mutant clones comprised nearly twice as much of the whole wing disc as did twin-spot tissue, while in control mosaic discs, the total areas of unmarked and twin-spot tissue are roughly the same (Figure 1F-H) . We also noticed that, particularly for the two null alleles, CtBP Q229 and CtBPN148 fs , mutant clones had smooth edges when compared to wildtype clones (Figure 1F, G) .
Overexpressing each individual protein isoform of CtBP in the wing pouch consistently led to an overall size reduction of the adult wing, as well as ectopic vein tissue, likely reflecting CtBP's dual roles in growth and patterning (Supplementary Figure S1 , B-E). However, the severity of these phenotypes was variable between isoforms and even when assessing the effects of a single isoform, particularly those that fell into the "short" category. In general, overexpression of the "long" isoforms resulted in smaller, rounder wings and mild ectopic vein formation while overexpression of the "short" isoforms reduced wing size while maintaining relatively a normal shape and in excessive ectopic veins (Supplementary Figure S1 B-E).
Overall, the phenotypes associated with both CtBP loss-of-function and overexpression indicate that CtBP functions as a negative regulator of growth.
CtBP limits tissue growth by repressing bantam expression
Given CtBP's identity as a transcriptional co-repressor, we explored the possibility that CtBP may normally restrict tissue growth by regulating the expression of known growth promoters.
We examined readouts of the Hippo pathway due to some similarities in phenotype to loss-offunction mutations in the Hippo pathway (mutant clones larger with smooth boundaries). We tested the effects of manipulating CtBP function on in vivo transcriptional reporters for the Yki target genes bantam (ban), expanded (ex), and Diap1, as well as the protein expression pattern of Yki. In CtBP Q229* clones, expression of a ban3-GFP enhancer reporter (Matakatsu and Blair, 2012) was increased, particularly near clonal boundaries (Figure 2A'-A") . We also observed a slight upregulation of ex expression (Supplemental Figure S2 A-A'''), as assessed by an ex-lacZ enhancer trap (ex 697 (Boedigheimer and Laughon, 1993) ) though this seemed to occur mostly along the cells in contact with wild-type tissue. Expression of a Diap1-GFP transgenic reporter (Zhang et al., 2008) , however, was unchanged in CtBP Q229* clones (Supplemental Figure S2 B The ban gene encodes a microRNA (miRNA) that promotes growth by stimulating cell proliferation and inhibiting apoptosis (Brennecke et al., 2003) . Consistent with the observed increase in ban3-GFP enhancer activity, a GFP-ban sensor, which inversely reports ban miRNA levels (Brennecke et al., 2003) showed decreased GFP levels in CtBP Q229* clones ( Figure 2B -B'''), thus indicating higher levels of ban miRNA activity. Conversely, FLP-out Gal4 clones that overexpress CtBP show higher GFP-ban sensor expression, indicating reduced ban miRNA levels (Figure 2C-C' ). We note that this effect is shown via overexpression of the short CtBP.I-HA isoform (Figure 2C-C' ), but we also tested the short CtBP.A-HA and long
CtBP.E-HA isoforms and observed increased GFP-ban sensor activity indicative of reduced ban expression in clones overexpressing these isoforms as well (not shown).
These results suggest that increased ban expression may be responsible for the overgrowth phenotype of CtBP mutant tissue. To assess this possibility, we tested whether reducing ban levels can suppress the overgrowth of CtBP mutant clones using the MARCM technique, which allows for the expression of UAS transgenes within mosaic clones (Lee and Luo, 1999) . Expression of a previously described ban sponge transgene (ban-sp), which contains repeated ban-binding sites to deplete the endogenous pool of available ban miRNA (Becam et al., 2011) , significantly reduced the growth of CtBP Q229* MARCM clones ( Figure 2H ). Taken together, these results suggest a role for CtBP in regulating tissue growth via repression of the growth-promoting miRNA ban.
CtBP regulates a minimal bantam enhancer, brC12 via Yorkie-dependent and Yorkieindependent mechanisms
We next searched for factors that might mechanistically link CtBP to ban regulation. Within the ban3 enhancer sequence used to generate the ban3-GFP reporter (Matakatsu and Blair, 2012) is an approximately 400 bp sequence, brC12 (Figure 3A) , that has been previously shown to function as a Yki-dependent minimal ban enhancer (Oh and Irvine, 2011) . When we tested whether this enhancer is sensitive to changes in CtBP, we detected upregulation of a brC12-lacZ reporter gene in CtBP Q229* mutant clones that were positively marked with GFP using MARCM ( Figure 3B-B'' ). Overexpressing CtBP in CtBP Q229* MARCM clones could fully suppress this increased enhancer activity (we show use of the long isoform E in Figure 3C -C'' but also observed a similar effect using the short isoform A). By identifying a minimal sequence by which CtBP is capable of regulating ban, we sought to use this readout to further probe the mechanism linking CtBP to tissue growth.
Because the minimal brC12 enhancer is known to be regulated in a Yki-dependent manner (Oh and Irvine, 2011) , we next tested whether yki is required for the increased reporter activity As outlined in Figure 3D , this will result in four genetically-distinct populations of cells distinguishable by their fluorescent markers: (1) cells that lack yki function but have at least one functional copy of CtBP are red; (2) cells that lack CtBP function but have at least one functional version of yki are green; (3) cells that have at least one functional copy of both yki and CtBP are yellow; and (4) cells that are double-mutant i.e. lack both yki and CtBP function also lack both fluorescent markers and hence appear black. Consistent with a previous report (Yu and Pan, 2018) and the results shown in Figure 3E -F', brC12-lacZ reporter activity is completely abolished in yki single-mutant tissue (single-asterisk in Figure 3E' ). Expression is elevated in CtBP single-mutant tissue (double-asterisk in Figure 3E' ) as compared to wild-type tissue (dotted outline in Figure 3D ', E'). If the upregulation of brC12 enhancer activity in CtBP mutant clones were solely due to excessive yki function, then double-mutant tissue would be predicted to have the same level of reporter activity as that found in yki single-mutant tissue.
However, brC12-lacZ expression actually appeared slightly higher in the double-mutant tissue (solid outline in Figure 3F -F') than in the yki single-mutant tissue (single-asterisk in Figure 3F Figure S3 ).
brC12 activity depends on a basal level of JNK signaling
We sought to further explore the Yki-independent component to ban regulation. We identified a putative AP-1 binding site, TGAGTCA (Angel et al., 1987) , within a highly conserved region of the brC12 sequence; AP-1 is the key downstream transcriptional effector of the JNK pathway suggesting that ban enhancer activity may be regulated by JNK signaling. To test this, we assayed the effects of various JNK pathway manipulations on the brC12-lacZ reporter, using a ptc-Gal4 driver. As shown in Figure 4A , brC12-lacZ is expressed relatively uniformly throughout the wing imaginal disc. Blocking JNK signaling via expression of a dominantnegative version of the Drosophila JNK protein Basket (Bsk-DN) (Adachi-Yamada et al., 1999) completely abolished reporter expression within the ptc-Gal4 stripe (Figure 4B ). This suggests that ban enhancer activity requires a basal level of JNK signaling that is normally present throughout undamaged discs.
Because the JNK pathway is known to promote apoptosis (reviewed by (Igaki, 2009) ), this can complicate interpretation of brC12-lacZ expression changes under conditions of JNK pathway over-activation, as growth effectors are often upregulated during compensatory growth of lost tissue (reviewed in (Worley et al., 2012) ). For instance, elevating pathway activity via knockdown of the JNK phosphatase puckered (puc) resulted in an increase in both brC12-lacZ expression and apoptosis, as detected by DCP-1 staining (Figure 4C) . However, when we mildly activated JNK signaling by overexpressing the JNK kinase Hemipterous (Hep) (Glise et al., 1995) , we observed elevated levels of brC12-lacZ expression without an appreciable increase in apoptosis ( Figure 4D) . Taken together, our results indicate that activity of the minimal ban enhancer is JNK-dependent and its activation by JNK can be uncoupled from JNK-induced apoptosis.
CtBP also regulates brC12 activity by antagonizing JNK signaling
Previously, while characterizing the role of CtBP in regulating regenerative plasticity, our group reported that loss of CtBP function results in the upregulation of several reporters of AP-1 activity (Worley et al., 2018) , suggesting that JNK and CtBP may have opposing effects on shared transcriptional targets (Figure 5A ). Since we have demonstrated the minimal ban enhancer is activated by JNK signaling, we hypothesized that CtBP may normally antagonize this effect, which could explain why brC12-lacZ expression is increased in CtBP mutant tissue.
To determine if CtBP regulates the ban enhancer in a JNK-dependent manner, we coexpressed Bsk-DN with CtBP-targeting shRNA using ptc-Gal4 and examined reporter expression. As described previously, shRNA-mediated knockdown can persist long after expression of the shRNA gene has ceased (Bosch et al., 2016) (Figure 5B) . Indeed, we observed persistent knockdown of the CtBP protein, as revealed by CtBP immunostaining, in cells that previously expressed, but stopped expressing Gal4 (Figure 5C ). Notably, we consistently observed increased levels of the brC12-lacZ reporter outside of the current ptc-Gal4 expression domain, indicated by UAS-GFP expression (marked by yellow brackets in (Figure 5C-D) . Taking advantage of the persistent CtBP knockdown caused by ptc-Gal4driven expression of the CtBP-shRNA transgene, we co-expressed the shorter-lived Bsk-DN protein, whose function is presumably limited to the current ptc>GFP domain, to compare brC12 enhancer activity in CtBP-knockdown tissue in the presence or absence of JNK signaling (Figure 5D) . Whereas brC12-lacZ levels were increased in cells lacking CtBP alone (marked by yellow brackets in Figure 5D ), knocking down CtBP and blocking JNK signaling together brought reporter expression down to levels similar to what we observed in the non-Gal4/UAS-expressing tissue (Figure 5D) . Thus, JNK signaling is required for the full upregulation of brC12 activity caused by loss of CtBP. Notably, co-expression of Bsk-DN and CtBP-shRNA did not appear to reduce reporter levels to the same extent observed when overexpressing Bsk-DN alone (compare Figure 5D' to Figure 4B" ), suggesting that there are JNK-independent mechanisms by which CtBP can regulate the brC12 enhancer.
Loss of distinct Fos isoforms leads to increased brC12 enhancer activity
Given CtBP's identity as a transcriptional co-repressor, one possible mechanism by which CtBP could antagonize JNK activity is through a functional interaction with AP-1. The AP-1 complex is typically thought of as a transcriptional activator, which, in Drosophila, is formed by heterodimeric interactions between the transcription factors Jun (also known as Jra) and Fos (also known as Kayak and Fra) (Perkins et al., 1988; Riesgo-Escovar and Hafen, 1997) ; reviewed by (Alfonso-Gonzalez and Riesgo-Escovar, 2018). The kayak gene has five annotated isoforms. Intriguingly, protein sequence analysis reveals that 2 of the 5 predicted isoforms of Fos, isoform A and isoform G, possess the canonical CtBP binding motif, PxDLS (Figure 6A) . Thus, we speculated that CtBP could be recruited to the ban locus by AP-1 complexes containing these Fos proteins to mediate transcriptional repression. If so, then eliminating these isoforms might phenocopy the effect of inactivating CtBP. To test this, we took advantage of a ∼17kb chromosomal deletion, Df(3R)ED6315 which removes 3 of the 4 alternatively spliced 5' exons of the fos gene and spans the transcriptional start sites for 3 of the 5 isoforms, including A and G (Figure 6A) . When we generated clones that are homozygous for this deletion (Figure 6B) , we observed elevated brC12-lacZ reporter levels within these clones (Figure 6B" ) (note that brC12-lacZ expression is elevated in the adjacent dorsal hinge even in wild-type tissue). The chromosomal region that is removed by the Df(3R)ED6315 deficiency also contains two additional genes, fos intronic gene (fig) (Figure   6A ), which encodes a predicted PP2C phosphatase (Hudson et al., 2007) , and the lncRNA CR46110 (not shown), neither of which have well-characterized functions. While we cannot exclude the possibility that elimination of one or more of these factors may be causing the observed increase in enhancer activity, given the analysis presented thus far, we take this result to raise the possibility that some Fos isoforms may have a repressive function.
To determine the overall effect of eliminating fos function, we knocked down fos using an shRNA that targets all isoforms (Figure 6C) . Expressing this shRNA using ptc-Gal4 had no appreciable effect on brC12-lacZ expression ( Figure 6C) . Immunostaining with an anti-Fos antibody confirmed Fos knockdown in the ptc-Gal4 expression domain and also revealed that Fos is present at very low levels throughout the disc proper (Figure 6C) , where most of our analyses of the brC12-lacZ reporter have so far been performed. Greater Fos protein expression was instead observed in the squamous portion of the peripodial epithelium ( Figure   6D) , where ptc-Gal4 expression is limited to only a thin strip of cells just anterior to this domain.
The results presented are thus far consistent with three possible models. In one, Fos is not required for regulation of brC12 enhancer activity, which is why fos knockdown had no effect on brC12-lacZ expression, and, despite the apparent AP-1 binding site identified in the minimal ban enhancer, JNK signaling activates the enhancer via a Fos/AP-1 independent mechanism.
In this scenario, brC12 reporter activity is sensitive to loss of some other factor removed by the Df(3R)ED6315 deficiency. A second model predicts that while Fos/AP-1 is normally involved in transcriptional activation, certain Fos isoforms may function, either primarily or in certain contexts, as transcriptional repressors. The result of knocking down all Fos isoforms could simply represent an "averaging" of these opposing effects. A third model could involve a hybrid of the first two models, in which JNK signaling activates the ban minimal enhancer via both AP-1-independent and AP-1-dependent mechanisms.
If distinct Fos isoforms do have specific effects on the brC12 enhancer, then overexpressing individual isoforms could offer insights into their specific functions. We examined two isoforms, D and A, both of which are predicted to be affected by the Df(3R)ED6315 deficiency, but only one of which, isoform A, has the CtBP-binding motif PxDLS. Overexpression of isoform D (also known as the α isoform but which we will henceforth refer to as Fos.D) resulted in an upregulation of brC12-lacZ expression (Figure 6E) , indicating that Fos.D is capable of activating the minimal enhancer. In contrast, overexpression of isoform A (also known as the β isoform but which we will henceforth refer to as Fos.A), which contains the PxDLS motif, did not upregulate brC12-lacZ expression ( Figure 6F) . Staining with an antibody that recognizes all Fos isoforms revealed that ectopic Fos.A was stably expressed to a greater degree, than ectopic Fos.D (Figure 6F''', E''') . Because Fos and Jun together have been shown to form more stable protein-DNA complexes and thereby activate transcription to a greater extent than either of the proteins alone (Perkins et al., 1990) , we also co-expressed Fos.A with Jun ( Figure 6G) . This did not result in any appreciable change in brC12 enhancer activity but was sufficient to upregulate a known target, Mmp1 as assessed by MMP1 antibody staining (Figure 6G''') . Thus, Fos.A does not appear to regulate the minimal ban enhancer under these conditions but is capable of increasing the expression of at least one other gene at least when overexpressed together with Jun. Thus it is possible that Fos.A activates transcription more weakly than Fos.D and that relative concentrations of specific isoforms of Fos, Jun and CtBP in individual cells could determine whether AP-1 functions as an activator or a repressor at specific promoters (Figure 6H ).
Discussion
We have shown that the transcriptional co-repressor CtBP functions to restrict growth, in significant part, via reducing the levels of the microRNA ban. The responsiveness of a well characterized ban enhancer, brC12, to changes in CtBP levels allowed us to identify the transcriptional regulators that are impacted by CtBP. We show that both Yki and AP-1 function at this enhancer and that CtBP can negatively regulate both of these inputs. In mammalian cells, YAP/TAZ and AP-1 have been shown to function synergistically at enhancers, especially to regulate genes that are involved in tumor progression and the acquisition of invasive characteristics. Our work raises the possibility that the mammalian orthologs of CtBP, CTBP1
and CTBP2 could function similarly to regulate the expression of genes regulated by those enhancers.
Regulation of ban by CtBP via the Hippo pathway
We identified an allele of CtBP in a screen for mutations that enabled homozygous mutant clones generated during eye development to outgrow their wild-type sister clones. The observation that CtBP mutant clones are larger than wild-type clones has been previously reported (Hoang et al., 2010) , but the mechanism was not understood. Here we show that the overgrowth of CtBP mutant clones is characterized by and is dependent upon the increased expression of ban. We also show that the activity of a 410-bp ban enhancer is negatively regulated by CtBP. This enhancer has previously been shown to be activated by Yki. By generating clones that are mutant for either CtBP or yki and also double-mutant yki -CtBPclones, we show that increased enhancer activity of brC12 in CtBP clones has both Ykidependent and Yki-independent components.
The mechanism by which Yki regulates brC12 has been the subject of some debate. Because the brC12 enhancer lacks a canonical Sd-binding motif, it was suggested that Yki could interact with the enhancer via a different DNA-binding protein such as Mad (Oh and Irvine, 2011) . However, a requirement for sd was subsequently demonstrated by showing that Yki cannot activate brc12 when sd function is removed (Yu and Pan, 2018) . One explanation that would be consistent with both of these observations might be that the Yki/Sd complex does not bind to the enhancer directly but rather via a protein-protein interaction with a different DNAbinding protein such as Mad. Indeed, it has recently been shown that in mammalian cells, a complex containing YAP1 and the Sd ortholog TEAD4 can bind to enhancers of ecdysoneregulated genes not by interacting with DNA sequences, but rather via another protein, estrogen receptor α, that is already bound to the enhancer (Zhu et al., 2019) . Recent studies also suggest a mechanism by which CtBP can function as a repressor of Sd-regulated genes.
CtBP can bind to the repressor Nerfin-1 (Guo et al., 2019) , which in turn can interact with Sd (Vissers et al., 2018) .
Regulation of bantam by the JNK/AP-1 pathway
While the JNK/AP-1 pathway is known to be activated in response to a variety of stress stimuli and has key roles in regeneration and tumorigenesis, its function in developmental growth is less understood. A role for the JNK pathway in regulating the growth of the wing disc is consistent with the original description of the phenotype of the hemipterous (hep) mutant where occasional viable escapers can lack wings; hep encodes a JNK kinase (JNKK) (Glise et al., 1995) . More recently, it has been reported that a localized stripe of phosphorylated ('active') JNK (pJNK) along the anterior-posterior (A/P) compartment boundary in the wing imaginal disc is critical for proper disc growth and that inhibiting this JNK activity results in a reduction in overall wing size (Willsey et al., 2016) . Despite using multiple anti-pJNK antibodies and a variety of staining conditions, we were unable to observe the reported pJNK stripe.
However, our finding that the brC12-lacZ reporter can detect a seemingly uniform basal level of JNK signaling throughout the wing imaginal disc (Figure 4B) is consistent with the idea that low levels of JNK activity are important for normal growth. Changes in brC12-lacZ reporter expression elicited by reducing JNK signaling were not, however, detected with the GFP-ban sensor suggesting that the level of activation of this pathway could be very low.
We have identified a consensus AP-1 binding site within a conserved region of this enhancer sequence and shown that ectopic expression of the Fos.D isoform can activate the enhancer indicating that this enhancer can be activated by the canonical JNK/AP-1 pathway. However, we also have evidence that other fos isoforms (Fos.A) act differently and could even repress the brC12 enhancer (Figure 6B) . We observe that clones that lack a subset of Fos isoforms, including those with a predicted CtBP binding motif, activate the brC12 enhancer, which suggests that the effects of Fos/AP-1 at this, and likely other enhancers, could be complex and depend on the relative levels of different isoforms including some that are capable of binding to CtBP (Figure 6H) . The idea that CtBP, through its interactions with distinct Fos isoforms, may switch AP-1 from a transcriptional activator to a repressor is an exciting one, and could potentially be generalized to other examples of AP-1-dependent transcriptional regulation. In fact, a study of circadian rhythm behavior in Drosophila has previously demonstrated a unique requirement for Fos.D in regulating Clock (Clk) expression via its isoform-specific interaction with the Clk repressor VRI (Ling et al., 2012) . However, we also note that human FOS and paralogs FOSB, FOSL1 and FOSL2 lack a PXDLS motif. However, FOS does have a PxxDLS motif. It is also unclear how thoroughly the possibility of alternative isoforms has been explored at the FOS locus.
In addition to regulating the brC12 enhancer via AP-1, JNK could conceivably also antagonize CtBP via the Yki-dependent branch of the pathway. JNK has been shown to increase Yki levels in the nucleus by phosphorylating Ajuba (Jub) which then inhibits Yki phosphorylation by Wts (Sun and Irvine, 2013) . The effects of JNK on Yki seem context-dependent, however, since JNK can also inhibit Yki activity by more indirect mechanisms (Enomoto et al., 2015) .
A potential role for CtBP as a tumor suppressor
We have now identified CtBP mutants in two different screens, one for mutations that increase plasticity during regeneration and another that detects mutations that increase tissue growth.
Both of these findings hint at a possible role for mammalian CtBP orthologs in cancer since cancer cells typically display both of these characteristics. Chromatin profiling of mammalian cancer cell lines has shown that sites occupied by TEAD4 are often close to AP-1 binding sites and that the two pathways can function synergistically to activate target genes (Verfaillie et al., 2015; Zanconato et al., 2015; Liu et al., 2016) . Indeed many of the genes that seem to be regulated in this way seem to function in tumor progression and in promoting cell motility and invasiveness. Given the ability of Drosophila CtBP to regulate both Yki-and and AP-1mediated gene expression it is possible that the mammalian CtBP proteins could also function at enhancers where these pathways converge. Although we have used an enhancer from the ban locus to study this phenomenon, since ban is not found in mammals, the relevant transcriptional targets must be different. Humans have two CtBP paralogs, CTBP1 and CTBP2, which could potentially function with some level of redundancy. Increased expression of both genes has been observed in some cancers suggesting that they could function as oncogenes (Dcona et al., 2017) . However, CtBP has also been shown to antagonize some of the oncogenic properties of the adenovirus E1a protein (Subramanian et al., 2013) , suggesting that CTBP1 and CTBP2 could also function as tumor suppressors. Although mutations in these genes have been detected in human cancers as per data generated by the TCGA Research Network (https://www.cancer.gov/tcga), at least to our knowledge, the functional consequences of these mutations have not been evaluated. Assessing the impact of the mutated forms of CTBP1 and CTBP2 on YAP/TEAD and AP-1 transcription could be informative. 
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